Shanghai, China

Rongqiang Liu

USPTO Granted Patents = 3 

 

Average Co-Inventor Count = 11.2

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2018-2019

Loading Chart...
Loading Chart...
3 patents (USPTO):

Title: Innovations of Inventor Rongqiang Liu in Shanghai

Introduction

Rongqiang Liu is an accomplished inventor based in Shanghai, China, known for his significant contributions to the field of pharmaceutical innovations. With a total of three patents, Liu has made remarkable strides in enhancing therapeutic methods related to erythropoietin production, particularly in the treatment of anemia.

Latest Patents

Among his latest innovations is a groundbreaking patent concerning inhibitors of HIF prolyl hydroxylase. This invention presents compounds that act to inhibit HIF prolyl hydroxylase, aimed at enhancing the endogenous production of erythropoietin. The implications of this innovation extend to treating conditions associated with reduced erythropoietin production, such as anemia. Furthermore, Liu has worked on pharmaceutical compositions that include these compounds, representing a significant advancement in therapeutic applications.

Career Highlights

Rongqiang Liu is primarily associated with Merck Sharp & Dohme Corporation, a leading global pharmaceutical company. His work at this prestigious organization showcases his dedication to advancing medical science through innovative research and development. His expertise in this area has contributed to vital advancements in treatments for various blood-related conditions.

Collaborations

Throughout his career, Liu has collaborated with several notable professionals, including Jiaqiang Cai and Alejandro Crespo. These collaborations reflect Liu's commitment to working alongside talented individuals, fostering a dynamic exchange of ideas that leads to innovative solutions in the pharmaceutical field.

Conclusion

Rongqiang Liu stands out as a significant figure in the realm of invention and innovation. His work in developing inhibitors of HIF prolyl hydroxylase demonstrates not only his creativity and technical expertise but also his commitment to improving patient outcomes through science. As he continues his work at Merck Sharp & Dohme Corporation, the impact of his inventions will surely resonate within the medical community and beyond.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…